Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.1.1.64: testosterone 17beta-dehydrogenase (NADP+)

This is an abbreviated version!
For detailed information about testosterone 17beta-dehydrogenase (NADP+), go to the full flat file.

Word Map on EC 1.1.1.64

Reaction

testosterone
+
NADP+
=
androstenedione
+
NADPH
+
H+

Synonyms

17-ketoreductase, 17beta-HSD, 17beta-HSD 3, 17beta-HSD type 3, 17beta-HSD type 5, 17beta-HSD-3, 17beta-HSD1, 17beta-HSD3, 17beta-HSD4, 17beta-HSD5, 17beta-hydroxysteroid dehydrogenase, 17beta-hydroxysteroid dehydrogenase 3, 17beta-hydroxysteroid dehydrogenase type 3, 17beta-hydroxysteroid dehydrogenase type 5, 17beta-hydroxysteroid dehydrogenases type 3, 17betaHSD3, 3beta-hydroxysteroid dehydrogenase type 3, AKR1C3, HSD17B3, More, NADP-dependent testosterone-17beta-oxidoreductase, type 3 17beta-HSD, type 3 17beta-hydroxysteroid dehydrogenase, type 5 17beta-hydroxysteroid dehydrogenase, type 5 beta-hydroxysteroid dehydrogenase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.64 testosterone 17beta-dehydrogenase (NADP+)

Application

Application on EC 1.1.1.64 - testosterone 17beta-dehydrogenase (NADP+)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
diagnostics
-
evaluation of 17beta-HSD3 enzymatic activity using androgen receptor-mediated transactivation is important for understanding and diagnosing the 46,XY disorder of sexual development caused by mutations of HSD17B3 genes which results in low testosterone production. A method is adapted that easily evaluates enzymatic activity of 17beta-HSD3 by quantifying the conversion from androstenedione to trestosterone using androgen receptor-mediated transactivation
drug development
testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. High-throughput inhibitor screening, overview
medicine